Guérin Marlène, Guillemot Johann, Thouënnon Erwan, Pierre Alice, El-Yamani Fatima-Zohra, Montero-Hadjadje Maité, Dubessy Christophe, Magoul Rabia, Lihrmann Isabelle, Anouar Youssef, Yon Laurent
Institut National de la Santé et de la Recherche Médicale (INSERM), U982, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, European Institute for Peptide Research (IFRMP 23), University of Rouen, Mont-Saint-Aignan, France.
Regul Pept. 2010 Nov 30;165(1):21-9. doi: 10.1016/j.regpep.2010.06.003. Epub 2010 Jun 18.
Pheochromocytomas are rare catecholamine-secreting tumors that arise from chromaffin tissue within the adrenal medulla and extra-adrenal sites. Typical clinical manifestations are sustained or paroxysmal hypertension, severe headaches, palpitations and sweating resulting from hormone excess. However, their presentation is highly variable and can mimic many other diseases. The diagnosis of pheochromocytomas depends mainly upon the demonstration of catecholamine excess by 24-h urinary catecholamines and metanephrines or plasma metanephrines. Occurrence of malignant pheochromocytomas can only be asserted by imaging of metastatic lesions, which are associated with a poor survival rate. The characterization of tissue, circulating or genetic markers is therefore crucial for the management of these tumors. Proteins of the granin family and their derived peptides are present in dense-core secretory vesicles and secreted into the bloodstream, making them useful markers for the identification of neuroendocrine cells and neoplasms. In this context, we will focus here on reviewing the distribution and characterization of granins and their processing products in normal and tumoral chromaffin cells, and their clinical usefulness for the diagnosis and prognosis of pheochromocytomas. It appears that, except SgIII, all members of the granin family i.e. CgA, CgB, SgII, SgIV-SgVII and proSAAS, and most of their derived peptides are present in adrenomedullary chromaffin cells and in pheochromocytes. Moreover, besides the routinely used CgA test assays, other assays have been developed to measure concentrations of tissue and/or circulating granins or their derived peptides in order to detect the occurrence of pheochromocytomas. In most cases, elevated levels of these entities were found, in correlation with tumor occurrence, while rarely discriminating between benign and malignant neoplasms. Nevertheless, measurement of the levels of granins and derived peptides improves the diagnostic sensitivity and may therefore provide a complementary tool for the management of pheochromocytomas. However, the existing data need to be substantiated in larger groups of patients, particularly in the case of malignant disease.
嗜铬细胞瘤是一种罕见的分泌儿茶酚胺的肿瘤,起源于肾上腺髓质和肾上腺外部位的嗜铬组织。典型的临床表现为因激素过量导致的持续性或阵发性高血压、严重头痛、心悸和出汗。然而,它们的表现高度可变,可模仿许多其他疾病。嗜铬细胞瘤的诊断主要依赖于通过24小时尿儿茶酚胺和甲氧基肾上腺素或血浆甲氧基肾上腺素来证明儿茶酚胺过量。恶性嗜铬细胞瘤的发生只能通过转移灶的影像学检查来确定,其生存率较低。因此,组织、循环或基因标志物的特征对于这些肿瘤的管理至关重要。嗜铬粒蛋白家族的蛋白质及其衍生肽存在于致密核心分泌小泡中,并分泌到血液中,使其成为识别神经内分泌细胞和肿瘤的有用标志物。在此背景下,我们将重点回顾嗜铬粒蛋白及其加工产物在正常和肿瘤性嗜铬细胞中的分布和特征,以及它们在嗜铬细胞瘤诊断和预后中的临床应用。似乎除了嗜铬粒蛋白III外,嗜铬粒蛋白家族的所有成员,即嗜铬粒蛋白A、嗜铬粒蛋白B、嗜铬粒蛋白II、嗜铬粒蛋白IV - 嗜铬粒蛋白VII和前嗜铬粒蛋白原相关神经肽,以及它们的大多数衍生肽都存在于肾上腺髓质嗜铬细胞和嗜铬细胞瘤细胞中。此外,除了常规使用的嗜铬粒蛋白A检测方法外,还开发了其他检测方法来测量组织和/或循环嗜铬粒蛋白或其衍生肽的浓度,以检测嗜铬细胞瘤的发生。在大多数情况下,发现这些物质的水平升高,与肿瘤的发生相关,但很少能区分良性和恶性肿瘤。然而,测量嗜铬粒蛋白和衍生肽的水平可提高诊断敏感性,因此可为嗜铬细胞瘤的管理提供一种补充工具。然而,现有数据需要在更大的患者群体中得到证实,尤其是在恶性疾病的情况下。